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BACKGROUND: TERT promotor mutations are present in >75% of bladder tumours; these 
mutations are also detectable in urine.  Previous studies have used urinary pellet DNA, and 
semi-quantitative methods unsuitable for detecting very low mutant allele frequencies.  
OBJECTIVE:  In this proof-of-principle study we use ddPCR to count the DNA molecules with 
wt and mutant TERT sequences in urinary cfDNA from patients whose bladder cancers 
harbour TERT mutations.  
METHODS: Urinary cfDNA prepared from the urine from 104 bladder cancer patients was 
analysed.  We determined the mutant allele frequency across stages and grades of disease, 
analysed concordance between cfDNA and tumour DNA, compared cfDNA with pellet DNA, 
and analysed the quantity and size distribution of cfDNA. 
RESULTS: In 71 of 77 patients with a 228 G>A/T mutant tumour, the mutation was also 
detected in urinary cfDNA by ddPCR; all 6 “false negatives” were low grade pTa tumours. 
Overall concordance between tissue and cfDNA mutation status was 92%, and 100% was 
achieved for high grade disease.  Median mutant allele frequencies in urinary cfDNA were 
3.4, 13.4 and 32.1% in grade 1, 2 and 3 disease. The 228 G>A/T mutation was not detected 
in urinary cfDNA in 26 out of 27 mutation-negative patients (96% specificity). 
CONCLUSIONS: Concordance between tumour DNA and urinary cfDNA is high, and TERT 228 
G>A/T ddPCR may prove useful for monitoring patients that harbour this mutation.  Mutant 
allele frequencies in cfDNA are often high, but assays capable of detecting very low mutant 
allele frequencies will be required to achieve high sensitivity in low grade disease. 




The current gold standard method for urothelial bladder cancer (UBC) detection in both the 
incident and surveillance settings is cystoscopy.  Much research has focused on reducing 
dependence upon this burdensome and expensive investigation by searching for urinary 
biomarkers which might enable non-invasive detection.  Such biomarkers might even permit 
surveillance via urine samples collected in patients’ own homes. 
Historically, urinary biomarker research has focussed on proteins and whilst work continues 
on developing panels of proteins with sufficient diagnostic accuracy, most proteins lack the 
sensitivity and specificity required for clinical utility (1).  Other classes of biomarkers such as 
mRNA and miRNA profiles and volatile organic compounds show promise; however, recently 
DNA-based biomarkers have come to the fore driven by technological developments and an 
increased understanding of the genomic and epigenetic mechanisms underpinning UBC 
(reviewed in (2)).  Bladder cancer is a heterogeneous disease so it is likely that a panel of 
biomarkers will be required to achieve high sensitivity (3, 4).  Detection of copy number 
changes, somatic mutations and DNA methylation in urine DNA have provided encouraging 
results (5-9).  Nonetheless, significant challenges remain to achieve clinically acceptable 
sensitivity and specificity: although urine should be an ideal source of biomarkers due to its 
direct contact with the tumour, extracting sufficient usable DNA from urine samples can be 
difficult, and the proportion of that DNA which originates from the tumour is variable.  The 
optimal analytical platform must therefore be able to cope with both low nanogram 
quantities of input DNA and low mutant allele frequencies.  In addition, all the components 
of a multimarker test would ideally be measurable using a single robust, rapid and 
inexpensive assay platform.   
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In 2013, mutations in the TERT promotor at position -124 and -146 bp relative to the TERT 
transcription start site were reported to be common events in UBC (10-13).  The mutations 
are at positions chr5:1,295,228 and chr5:1,295,250 (hg19), hereby referred to as “228” and 
“250”.  The 228 G>A is a particularly strong biomarker candidate as this single base 
substitution has been reported to be present in 53-66% of UBCs, and across all stages and 
grades of disease (12, 14, 15).  Several studies have reported the detection of TERT 
promotor mutations in DNA from urine cell pellets (7, 10, 16, 17).  However, there is 
evidence that urinary cfDNA may more faithfully recapitulate whole tumour DNA than the 
more commonly used urinary cell pellet DNA (9, 18, 19).  The high frequency of TERT 
mutations in UBC make them key constituents of any somatic mutation panel for detecting 
primary UBC; a large mutation panel including TERT mutations may be required for 
detecting primary disease but following index tumour sequencing a smaller personalised 
mutation panel could suffice for surveillance and TERT mutations would be useful for the 
majority of patients.  We hypothesise that because of the number of mutations required, a 
large panel for initial detection is likely to be NGS based (7), whereas smaller personalised 
panels for surveillance could be based on ddPCR with its ability to detect very low mutant 
allele frequencies but limited ability to detect multiple mutations (19, 20).   
In this study, we investigate the use of digital droplet PCR for the TERT 228 G>A mutation to 
determine mutant allele frequency and hence “tumour burden” in urinary cfDNA and 
compare with cell pellet DNA and tumour DNA next generation sequencing data.  We also 
characterise the size and quantity of DNA across different stages and grades of bladder 
cancer.  We conclude that the application of TERT mutation ddPCR to urinary cfDNA 
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warrants further examination as a personalised assay for the surveillance of UBC patients 
whose tumours harbour this mutation.   
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MATERIALS AND METHODS 
Patients & Specimens 
Urine and tissue specimens were prospectively collected for biomarker research between 
2006 and 2011 as part of the Bladder Cancer Prognosis Programme (BCPP, ethics approval 
06/MRE04/65) (21).  All UBC patients were newly-diagnosed and had not received 
treatment prior to urine or tissue collection.  Inclusion and exclusion criteria are detailed 
elsewhere (21).  Urine specimens were placed on ice, centrifuged at 2000g for 10 minutes 
within 8 hours of collection, and supernatants and pellets stored at -80°C.  Tissue specimens 
were collected at the time of transurethral resection (TURBT), snap-frozen in liquid nitrogen 
and stored at -80°C. 
DNA was extracted from 135 paired frozen tumours and urine supernatants (cfDNA); DNA 
was also extracted from 17 accompanying urine pellets.  The 135 patients were selected 
from the larger BCPP study on the basis that they were within the 50% of BCPP tumours 
subjected to targeted NGS and hence with known TERT mutation status (manuscript in 
preparation) and had >10 ml of urine supernatant available for cfDNA preparation.  No 
attempt was made to select on the basis of stage or grade. 
Tumour Next Generation Sequencing 
DNA was extracted from 25 mg frozen tissue using the DNeasy Blood and Tissue kit (Qiagen, 
#69506).  The TERT promotor mutation status of every tumour was determined by targeted 
next generation sequencing (NGS) as described previously (7). 
Urine ddPCR 
Approximately 50 ml of urine was processed per patient, with 10 ml of urinary supernatant 
or the entire pellet utilised for DNA extraction using the Quick-DNA Urine kit (Zymo, D3061).  
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DNA concentrations were determined using the Qubit high sensitivity DNA kit (Thermo, 
#Q32854) and cfDNA size determined by Bioanalyzer using high sensitivity chips (Agilent, # 
5067-4626).  cfDNA preparations from 104 patients yielded >10 ng DNA and were included 
for analysis.  The overall study design and patient demographics are shown in Supplemental 
Figure S1 and Table S1.    The number of wt and TERT 228 G>A/T DNA molecules was 
determined in all urinary DNAs and 21 of the tumour DNAs by digital droplet PCR using the 
TERT_C228T liquid biopsy assay (Thermo, #A44177), supermix for probes (Biorad, 
#1863010) and the Biorad QX200 droplet formation/reader system (Biorad).  The PCR 
program consisted of 10 minutes at 96°C followed by 54 cycles of 98°C x 30 sec and 55 °C x 2 






Assay validation   
The TERT promotor sequence is both repetitive and GC rich; in our experience, many 
polymerases fail to amplify this region.  We therefore commenced by comparing the levels 
of TERT mutation found by ddPCR versus an established NGS workflow (7) in DNA extracted 
from 21 fresh-frozen tumours.  As shown in Figure 1a, good agreement between the 2 
methods was observed.  We found that ddPCR yields a positive result with the less common 
228 G>T mutation as well as the 228 G>A mutation.   The ddPCR assay also performed well 
in a serial dilution of mutant DNA (Figure 1b). 
 
cfDNA analysis of urinary DNA 
ddPCR was used to analyse urinary cfDNAs from 104 UBC patients.  All of these patients had 
the TERT promotor sequenced in their tumour DNA by NGS (12 x wt, 15 x 250A, 75 x 228A 
and 2 x 228T).  The mutant allele frequency as determined by ddPCR is shown for every 
cfDNA analysed in Figure 2.  cfDNA from the 27 patients with tumours negative for a 228 
mutation gave very low levels of mutant positive droplets and allowed us to define a 
threshold of 1% mutant allele frequency (MAF) for a “positive result” (mean + 2SD).  The 
cfDNA result from 26 of the 27 wt or 250 G>A tumours were below this threshold.  
Analysing the cfDNA from patients with a TERT 228 G>A/T positive tumour by NGS gave a 
positive result in 71 out of 77 cases (92%): 24 of 30 mutant positive pTa tumours (80%) gave 
a positive result, and all pT1 (n=19) and MIBC (n=27) cases gave a positive result.  All 6 
“false-negative” results were from patients with grade 1 pTa disease, and there were no 
false-negatives amongst higher grades and stages.  The cfDNA MAF data is summarised in 
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Figure 3.  These data show that MAF is strongly influenced by tumour grade and size, but 
less so by stage of disease, cfDNA concentration or the number of tumours.  
    
ddPCR analysis of urinary cfDNA and cell pellet DNA  
Figure 4 plots the TERT MAF detected by ddPCR for 17 paired cfDNAs and cell pellet DNAs 
(both types of DNA extracted from the same urine void).  There is a positive correlation 
between tumour content in the two types of DNA (r2 = 0.73), although there is also scatter 
in the data indicating that the MAF in the two types of DNA may differ in any individual 
patient.  The average MAF was not significantly different between cfDNA and pellet DNA. 
 
Quantification and size analysis of urinary cfDNA in UBC patients  
cfDNA was prepared from 10 ml of each urine supernatant.  The median yield of cfDNA was 
39ng (3.9 ng/ml urine); however, yield was highly variable and 10 samples yielded less than 
1 ng of cfDNA.  Yield was dependent on the stage, grade and size but not the number of 
tumours (Figure 5).  The Bioanalyzer gel electrophoresis system was used to analyse the size 
distribution of urinary cfDNA in UBC patients.  The vast majority of samples presented with 
a peak of approximately 178 bp consistent with mononucleosomal cfDNA (Figure 6).  Di- and 
trinucleosomal DNA was also evident in most samples along with a variable amount of 
longer DNA (1-10 kb).   The ratio of 178 bp DNA to longer fragments was highly variable 
although on average 50% of the intensity of the Bioanalyzer traces was >300bp.  We found 
no relationship between the ratio of 178 bp DNA to longer fragments and MAF suggesting 
that the tumour:normal ratio is similar in both types of DNA and that targeting urinary 
cfDNA of a particular size category would not aid in biomarker detection.  To corroborate 
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this result, we applied Pronex bead fractionation (Promega) to 8 of the higher concentration 
cfDNAs.  This method produced 2 fractions for each sample: one enriched for shorter 
fragments and one enriched for longer fragments (Figure S2 Supplemental Information).  









We have used ddPCR to count the number of wt and TERT 228A mutant molecules in the 
urinary cfDNA of patients with varying stages and grades of UBC.  In patients whose tumours 
contained the TERT 228 G>A/T mutation, we were able to detect the mutation in urinary 
cfDNA with a sensitivity of 92%.  It is therefore likely that the combination of ddPCR and 
cfDNA for this common mutation in bladder cancer could play a role in disease surveillance.  
It should be noted that 31 patients had <10ng of DNA extracted from the 10mls of urine, 
and were excluded from the analyses.  Thus, the reported sensitivities and specificities 
relate only to those samples which did generate enough DNA to be assayed. The excluded 
patients comprised 4 MIBC, 5 pT1 and 22 pTa and had a mean tumour diameter of 2.7 cm 
(compared with 3.7 cm for the remainder of the cohort).  DNA extraction from a larger 
volume of urine would likely resolve this issue. We found that the assay detects both G>A 
and G>T substitutions at position 228 (but not at the 250 position), and that 74% of the 
patients in this study had one or other substitution at position 228.   
We envisage that index tumour sequencing is likely to be routine in the not too distant 
future and that this would enable selection of a small panel of somatic mutations for 
personalised non-invasive surveillance.  Such panels could be ddPCR based and the TERT 
228 G>A/T mutation would be a core component for many patients.  Although limited in its 
ability to multiplex biomarkers, ddPCR is well suited to detecting rare mutations and is 
inexpensive, fast, reliable and gives absolute quantitation (22).  Tumour evolution might 
compromise the use of mutations for surveillance; however, in NMIBC recurrences occur as 
a result of incomplete resection of the primary urothelial cancer, tumour cell re-
implantation, growth of microscopic tumours present at the time of the previous resection, 
or genuine new tumour formation (23).  Although bladder cancer is a heterogeneous 
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disease, it is also a disease in which synchronous and metachronous tumours demonstrate 
“clonality” (2). Thus, it can be reasonably assumed that mutations in the primary index 
tumour will remain as characteristics of new tumours and be detectable in body fluids, as 
others have demonstrated (19, 20, 24).  In the specific case of TERT, mutations are 
considered to be early events in bladder carcinogenesis and are frequent across all stages of 
disease suggesting that loss of TERT mutations during tumour evolution is rare (14).  
Moreover, Brown et al recently reported that TERT mutations are conserved both spatially 
and temporally in UBCs (25).  Additional benefits of facile TERT mutation detection via 
urinary DNA could include treatment selection and prediction of recurrence and survival 
(12, 16, 26). 
We found that the MAF in urinary cfDNA is surprisingly high (median = 18%), but high inter-
patient variability is observed and levels are much lower in low grade disease.  We also 
analysed the size of urinary cfDNA and found that whilst both mononucleosomal and longer 
DNA fragments are present in variable proportions, both appear to contain tumour DNA.  
Our data suggest that an analytical method with a limit of detection of 1% mutant allele 
frequency would detect most grade 2 and 3 tumours, but that an even higher analytical 
sensitivity is required to detect elusive grade 1 cases.  In principle, ddPCR should allow 
detection of mutant alleles at much lower than 1% frequency; however, in our hands a small 
number of TERT mutation positive droplets were detected in DNA derived from patients 
with TERT wt tumours (see Figure S3) and this background “noise” limits analytical 
sensitivity.  The positive droplets could be due to PCR errors arising from the GC-rich nature 
of the TERT-promotor, sample contamination, or possibly in some cases, sub-clonality, i.e. 
TERT mutations in areas of the tumour or urothelium that were not sequenced.   
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In contrast to previous studies favouring urinary cfDNA over pellet DNA for recapitulating 
tumour genomics (9, 18, 19), the limited comparison of urinary cfDNA and cell pellet DNA in 
this study (n=17, Figure 4) did not show a clear advantage to using cfDNA over pellet DNA 
for the detection of the TERT 228 G>A/T mutation.  In this scenario, the higher DNA yield 
typically achieved from cell pellets may favour their use in diagnostic testing: larger scale 
studies are required for comprehensive comparison of the two sources of DNA. 
In conclusion, ddPCR detection of TERT mutations in urinary cfDNA holds promise for the 
non-invasive detection of UBCs known to harbour these mutations (approximately three 
quarters of all patients). The current work has analysed urinary cfDNA from more individual 
patients than previous studies and adds to a body of evidence supporting urinary cfDNA as a 
suitable substrate for the non-invasive detection of UBC (9, 18-20).   
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 Figure Legends 
 
Figure 1.  ddPCR validation.  Figure 1A shows the TERT 228 G>A/T mutant allele frequency 
in DNA extracted from 21 fresh-frozen bladder tumours measured by ddPCR and NGS.  
Figure 1B shows ddPCR analysis of a 2-fold serial dilution of pooled TERT mutant tumour 
DNA (15% mutant by NGS) diluted in pooled TERT wt tumour DNA. 
Figure 2.  TERT 228 G>A/T mutant allele frequencies in the cfDNA of 104 UBC patients.  
The mutant allele frequency for each patient in the study is represented by a single bar.  
Patients  are sorted within each group by mutant allele frequency.  The groups are: UBCs 
with wt TERT promotor, UBCs with TERT 250 G>A mutant promotor and UBCs with TERT 
G>228A/T separated into pTa, pT1 and pT2+ disease. 
Figure 3.  TERT mutant allele frequencies in cfDNA.  The 6 panels show the influence of, A: 
tumour mutation status, B: tumour grade, C: tumour size, D: disease stage, E: cfDNA 
concentration (</> median level) and F: number of tumours on cfDNA TERT mutant allle 
frequency determined by ddPCR. 
Figure 4.  Comparison of mutant allele frequencies in urinary cfDNA and cell pellet DNA.  
17 paired samples were analysed by ddPCR. 
Figure 5.  Factors which influence urinary cfDNA concentration.  All DNA concentrations 
were determined using the Qubit HS double-stranded DNA kit.  Fig 5a: the effect of tumour 
grade on urinary cfDNA, 5b: effect of stage, 5c: effect of tumour size, 5d: effect of the 
number of tumours. 
Figure 6.  Bioanalyzer analysis of urinary cfDNA from UBC patients.  Each trace is for a 
cfDNA from a different patient.  The traces show the amounts of 1: mononucleosomal, 2: di- 
and tri-nucleosomal and 3: longer (1-10 kb) DNA fragments.   
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pTa 44 18/23/3/0 72.52 36/8 8 5 1 30 
pT1 29 0/8/20/1 70.77 27/2 3 7 0 19 
pT2+ 31 0/1/28/2 76.42 27/4 1 3 1 26 
 
Table S1.  Patient demographics.  For the cohort of 104 UBC patients whose cfDNA were analysed by 
ddPCR we show the number of patients with each stage and grade of disease 
(G1/G2/G3/unrecorded), median age (years), gender (no. male/female) and the mutation status of 
their tumour TERT mutation staus. 
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n=135
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Figure S2.  Size fractionation of urinary cfDNA.  Panels A and B show tapestation traces of two 
urinary cfDNAs fractionated using Pronex beads. 1: unfractionated cfDNA, 2: short fragment fraction, 














Figure S3. Example urinary cfDNA ddPCR data. Green: droplets
containing only wt TERT DNA, blue: droplets containing only TERT 228
G>A DNA, orange: droplets containing both wt and TERT 228 G>A DNA,
grey: droplets not containing DNA/PCR product.
Patient A: tumour = TERT 228 G>A 
Patient B: tumour = TERT 228 G>A 
Patient C: tumour = TERT wt
Patient D: tumour = TERT 250 G>A 
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